- Home
- ANSC vs RAPT Comparison
ANSC vs RAPT Comparison
Compare ANSC & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$32.88
Company Overview
Basic Information| Metric | ANSC | RAPT |
|---|---|---|
| Founded | 2021 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 466.6M | 498.4M |
| IPO Year | 2023 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ANSC | RAPT |
|---|---|---|
| Price | $11.17 | $32.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $57.00 |
| AVG Volume (30 Days) | 77.4K | ★ 407.1K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $54.78 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.48 | $5.67 |
| 52 Week High | $11.19 | $42.39 |
Technical Indicators
Market Signals| Indicator | ANSC | RAPT |
|---|---|---|
| Relative Strength Index (RSI) | 61.25 | 49.40 |
| Support Level | $11.12 | $33.01 |
| Resistance Level | $11.10 | $33.24 |
| Average True Range (ATR) | 0.02 | 2.04 |
| MACD | -0.00 | -0.50 |
| Stochastic Oscillator | 71.43 | 35.78 |
Price Performance
Historical Comparison ANSC
RAPT
About ANSC Agriculture & Natural Solutions Acquisition Corporation
Agriculture & Natural Solutions Acquisition Corp is a blank check company.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.